HK Stock Market Move | ABBISKO-B(02256) rose more than 5% recently with the latest clinical developments of ibrutinib and piminitinib announced at the ESMO annual meeting.
With Honors-B (02256) rose over 5%, as of the time of publication, it increased by 5.77%, closing at 3.3 Hong Kong dollars, with a turnover of 3.8013 million Hong Kong dollars.
ABBISKO-B(02256) rose over 5%, as of the time of publication, it rose by 5.77% to HKD 3.3, with a turnover of 3.8013 million Hong Kong dollars.
On the news front, Heyo Pharmaceutical recently announced that the company presented the latest clinical data on the safety and efficacy of its independently developed small molecule FGFR4 inhibitor, ipatinib (ABSK011), in Phase 1 clinical trials for advanced liver cancer with FGF19 overexpression at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting. It is worth mentioning that this study also won the "Best Poster Award" at the ESMO conference.
Data shows that the ipatinib 220mg BID group demonstrated excellent efficacy in FGF19-overexpressing liver cancer patients treated with immune checkpoint inhibitors (ICIs) and multi-targeted small molecule receptor tyrosine kinase inhibitors (mTKIs), with an overall response rate (ORR) of 44.8%, a median duration of response (mDOR) of 7.4 months, and a median progression-free survival (mPFS) of 5.5 months.
Related Articles
HK Stock Market Move | SHOUCHENG (00697) fell more than 8%, achieving a net profit of HK$310 million for the entire year, planning to distribute a final dividend of 0.47 Hong Kong cents.
CICC: Maintains outperform rating on GUMING (01364) with a target price of HK$36
HK Stock Market Move | BEAUTYFARM MED's stock price dropped more than 11% after the performance report, with a total decline of over 30% for the year. The full-year adjusted net profit increased by over 40% year-on-year.
HK Stock Market Move | SHOUCHENG (00697) fell more than 8%, achieving a net profit of HK$310 million for the entire year, planning to distribute a final dividend of 0.47 Hong Kong cents.
CICC: Maintains outperform rating on GUMING (01364) with a target price of HK$36
HK Stock Market Move | BEAUTYFARM MED's stock price dropped more than 11% after the performance report, with a total decline of over 30% for the year. The full-year adjusted net profit increased by over 40% year-on-year.
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026
